Paul Anthony Williams net worth and biography

Paul Williams Biography and Net Worth

SVP, Products Business of Emergent Biosolutions

Paul is an inspiring and strategic executive leader who thrives on working with people who are saving lives every day. He enjoys fostering an environment where communication and camaraderie flourish to impact not only employees but also patients who depend on Emergent’s work.

Paul’s extensive career in healthcare and pharmaceuticals has driven change in how global public health threats, including infectious diseases and substance use disorders, are prevented and treated.

What is Paul Anthony Williams' net worth?: The estimated net worth of Paul Anthony Williams is at least $1.20 million as of July 1st, 2026. Mr. Williams owns 159,098 shares of Emergent Biosolutions stock worth more than $1,204,372 as of July 14th. This net worth evaluation does not reflect any other assets that Mr. Williams may own. Learn More about Paul Anthony Williams' net worth.
How do I contact Paul Anthony Williams?: The corporate mailing address for Mr. Williams and other Emergent Biosolutions executives is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. Emergent Biosolutions can also be reached via phone at (240) 631-3200 and via email at [email protected]. Learn More on Paul Anthony Williams' contact information.
Has Paul Anthony Williams been buying or selling shares of Emergent Biosolutions?: During the past quarter, Paul Anthony Williams has sold $25,200.00 in shares of Emergent Biosolutions stock. Most recently, Paul Anthony Williams sold 3,000 shares of the business's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a transaction totalling $25,200.00. Following the completion of the sale, the senior vice president now directly owns 159,098 shares of the company's stock, valued at $1,336,423.20. Learn More on Paul Anthony Williams' trading history.
Who are Emergent Biosolutions' active insiders?: Emergent Biosolutions' insider roster includes Sujata Dayal (Director), Donald Degolyer (Director), Neal Fowler (Director), Coleen Glessner (EVP), Keith Katkin (Director), Richard Lindahl (CFO), Ronald Richard (Director), Paul Williams (SVP, Products Business), and Kathryn Zoon (Director). Learn More on Emergent Biosolutions' active insiders.
Are insiders buying or selling shares of Emergent Biosolutions?: During the last twelve months, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 132,447 shares worth more than $1,243,444.18. The most recent insider tranaction occured on July, 1st when SVP Paul Anthony Williams sold 3,000 shares worth more than $25,200.00. Insiders at Emergent Biosolutions own 6.0% of the company. Learn More about insider trades at Emergent Biosolutions.
Information on this page was last updated on 7/1/2026.

Paul Anthony Williams Insider Trading History at Emergent Biosolutions

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/1/2026	Sell	3,000	$8.40	$25,200.00	159,098

Paul Anthony Williams Buying and Selling Activity at Emergent Biosolutions

Emergent Biosolutions Company Overview

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $7.60

$7.39

$8.01

50 Day Range

MA: $8.37

$7.59

$9.50

2 Week Range

Now: $7.60

$5.61

$14.06

Volume

716,711 shs

Average Volume

876,571 shs

Market Capitalization

$391.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.34